ICB/PPGBAIP Estudo epidemiológico e monitoramento de Lamivudina (3TC) e Zidovudina (AZT) na terapêutica do HIV-1 em pacientes de Belém – PA e suas correlações com as funções hepática, renal e nutricional, Belém, Pará

Abstract

There are 39.5 million people living with HIV in the world. In Brazil, the Health Ministry indicates therapy for patients with clinical disease associated to HIV-1 and for those with lymphocytes T CD4+ level lower than 200 cels/ mm3. Together with the antiretroviral therapy benefits, toxics effects like miopathy, lipodistrofy, pancreatities, hepatotoxicities and lactic acidosis were recognized. The complexity of therapy regiments makes the compliance of this regiments difficult and this contributes to therapeutic failure. In this work, we have studied epidemiology, therapeutic monitoring of Lamivudine (3TC) and Zidovudine (AZT) and its correlation with hepatic, renal and nutritional function on HIV-infected patients, admitted to CASA DIA, Belém/PA. The population studied was 60 HIV-infected patients of both genders, with age range from 20 to 61 years old, treated with AZT and/or 3TC. We measured plasmatic levels of aminotranspherasis, urea, and creatinine by using absorption’s photometry, and 3TC and AZT concentrations by Hight Performance Liquid Chromatography. The nutritional state was evaluated by measuring the body mass index (BMI). The 3TC concentration range was 1.283 to 355.953 μg/mL, while AZT was 0.008 to 22.544 μg/mL. The 3TC plasmatic levels have revealed association with occupation (p < 0.05) and creatinine levels (p < 0.0001), but not with aminotranspherasis and urea levels (p > 0.05). There was not any association between AZT plasmatic levels and the demographic parameters (age, school level, occupation, pregnancy, serology revealed during pregnancy, infection time, vitamins supplements, use of alcohol and tobacco) and creatinine levels (p > 0.05), nevertheless we have found association with aminotranspherasis and urea (p < 0.0001). BMI has revealed association with all studied parameters: 3TC, AZT, aminotranspherasis, urea and creatinine levels (p < 0.05). We have concluded that 3TC plasmatic levels can alter creatinine levels and can be influenced by the nutritional state of patients, while AZT levels can alter aminotranspherasis levels, urea and can be influenced by the nutritional state, too, confirming the pharmacokinetics processes of both drugs.